Anand Lokare

1.9k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

Anand Lokare is a scholar working on Internal Medicine, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Anand Lokare has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Internal Medicine, 9 papers in Hematology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Anand Lokare's work include Venous Thromboembolism Diagnosis and Management (10 papers), Multiple Myeloma Research and Treatments (7 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Anand Lokare is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (10 papers), Multiple Myeloma Research and Treatments (7 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Anand Lokare collaborates with scholars based in United Kingdom, Canada and India. Anand Lokare's co-authors include Oliver Chapman, Janet Dunn, Annie Young, Catherine St. Hill, Andrea Marshall, Mark N. Levine, Danielle Hale, Richard Hobbs, Anthony Maraveyas and Stavros Petrou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Anand Lokare

18 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

2018 855 citations Annie Young, Andrea Marshall et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Anand Lokare

Since Specialization

Citations

This map shows the geographic impact of Anand Lokare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anand Lokare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anand Lokare more than expected).

Fields of papers citing papers by Anand Lokare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anand Lokare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anand Lokare. The network helps show where Anand Lokare may publish in the future.

Co-authorship network of co-authors of Anand Lokare

This figure shows the co-authorship network connecting the top 25 collaborators of Anand Lokare. A scholar is included among the top collaborators of Anand Lokare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anand Lokare. Anand Lokare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial 2024 ·Blood ·Martin Kaiser, Andrew Hall, (unknown), Amy Holroyd, Eugene B. Ferris, (unknown), (unknown), Kristian M. Bowles, Mamta Garg, Anand Lokare, Ruth M. de Tute, Mark T. Drayson, Christina Messiou, Roger G. Owen, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Sarah Brown, Matthew Jenner	0
2	Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma 2023 ·Journal of Clinical Oncology ·Martin Kaiser, Andrew Hall, Katrina Walker, Amy L. Sherborne, Ruth M. de Tute, (unknown), (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah Brown, Matthew Jenner	54
3	Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial 2022 ·Blood ·Martin Kaiser, Andrew Hall, Isabelle L Smith, Ruth M. de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Mark T. Drayson, Roger G. Owen, Sarah Brown, Matthew Jenner	9
4	PO-36 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial 2021 ·Thrombosis Research ·(unknown), (unknown), (unknown), Cameron Hill, Diane F. Hale, (unknown), (unknown), (unknown), A.K. Kakkar, Anand Lokare, Anthony Maraveyas, Oliver Chapman, Ahmed A. Arif, (unknown), Mandy Maredza, Richard Hobbs, (unknown)	0
5	Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial. 2021 ·Journal of Clinical Oncology ·Martin Kaiser, Andrew Hall, Katrina Walker, Ruth de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Mark T. Drayson, Roger G. Owen, Sarah Brown, Matthew Jenner	11
6	Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial 2021 ·Blood ·Matthew Jenner, Andrew Hall, Sian Faustini, (unknown), Ruth M. de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Roger G. Owen, Sarah Brown, Mark T. Drayson, Martin Kaiser	2
7	Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial 2021 ·Blood ·Martin Kaiser, Andrew Hall, Katrina Walker, (unknown), Ruth M. de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah Brown, Matthew Jenner	8
8	OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Martin Kaiser, Andrew Hall, Katrina Walker, Ruth de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Mark T. Drayson, Roger G. Owen, Sarah Brown, Matthew Jenner	1
9	Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: a role for direct anticoagulants? 2020 ·Journal of Thrombosis and Thrombolysis ·(unknown), Anand Lokare, Husam Osman, (unknown), (unknown), (unknown), (unknown), (unknown)	8
10	Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m) 2020 ·Journal of Thrombosis and Haemostasis ·Andrea Marshall, Mark N. Levine, Catherine St. Hill, Danielle Hale, (unknown), (unknown), (unknown), (unknown), Anand Lokare, Anthony Maraveyas, Oliver Chapman, (unknown), Stavros Petrou, Mandy Maredza, Richard Hobbs, Janet Dunn, Annie Young	55
11	Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes 2020 ·Journal of Thrombosis and Thrombolysis ·Graham McIlroy, Neil R. Smith, Anand Lokare, (unknown), (unknown)	5
12	Thrombocytopenia as an initial manifestation of COVID‐19; case series and literature review 2020 ·British Journal of Haematology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anand Lokare, Joanne Ewing, Shankara Paneesha, Vidhya Murthy	30
13	Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D) breakdown → 2018 ·Journal of Clinical Oncology ·Annie Young, Andrea Marshall, (unknown), Oliver Chapman, Anand Lokare, Catherine St. Hill, Danielle Hale, Janet Dunn, Gary H. Lyman, Charles Hutchinson, Peter MacCallum, Ajay K. Kakkar, Richard Hobbs, Stavros Petrou, Jeremy Dale, Christopher Poole, Anthony Maraveyas, Mark N. Levine	855
14	Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the ‘select-d’ Pilot Trial 2018 ·Thrombosis Research ·Annie Young, Andrea Marshall, (unknown), Oliver Chapman, Anand Lokare, Catherine St. Hill, Danielle Hale, Janet Dunn, A.K. Kakkar, Mark N. Levine	31
15	Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients 2018 ·Blood ·Graham McIlroy, Neil R. Smith, Anand Lokare, (unknown), (unknown)	6
16	Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial 2017 ·Blood ·Annie Young, Andrea Marshall, (unknown), Catherine St. Hill, Danielle Hale, Janet Dunn, Anand Lokare, Ajay K. Kakkar, Mark N. Levine, Oliver Chapman	23
17	OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism 2016 ·Thrombosis Research ·Annie Young, Jane Phillips, (unknown), Catherine St. Hill, (unknown), A. Marshall, (unknown), Janet Dunn, Anand Lokare, Oliver Chapman	30
18	Reduced Intensity Allogeneic Stem Cell Transplant for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm 2014 ·Hematology Reports ·Anand Lokare, Emmanouil Nikolousis, Neil Phillips, (unknown), Richard Lovell, Bhuvan Kishore, Don Milligan, Shankara Paneesha	4
19	SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. 2014 ·Journal of Clinical Oncology ·Annie Young, Janet Dunn, Oliver Chapman, (unknown), Andrea Marshall, (unknown), Anand Lokare, (unknown)	7
20	Intrapulmonary vascular dilatations with hypoxemia in extrahepatic portal vein obstruction. 1993 ·PubMed ·(unknown), (unknown), (unknown), Philip Abraham, (unknown), (unknown), Anand Lokare	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact